Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) have earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $351.67.

Several equities analysts have issued reports on MDGL shares. B. Riley boosted their price objective on shares of Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. UBS Group boosted their price objective on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. JMP Securities restated a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Finally, Oppenheimer decreased their target price on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL opened at $339.97 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The stock has a market capitalization of $7.41 billion, a P/E ratio of -13.56 and a beta of -0.38. The company’s fifty day moving average is $314.42 and its two-hundred day moving average is $276.65. Madrigal Pharmaceuticals has a 1 year low of $168.25 and a 1 year high of $368.29.

Insider Buying and Selling

In related news, Director Fred B. Craves sold 3,600 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $315.31, for a total value of $1,135,116.00. Following the sale, the director now directly owns 11,000 shares in the company, valued at $3,468,410. The trade was a 24.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert E. Waltermire sold 442 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $120,847.22. Following the completion of the sale, the vice president now owns 5,058 shares in the company, valued at $1,382,907.78. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,090 shares of company stock worth $3,883,621 in the last three months. Corporate insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its holdings in Madrigal Pharmaceuticals by 47.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 68 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in Madrigal Pharmaceuticals in the 4th quarter valued at about $70,000. Quest Partners LLC lifted its holdings in Madrigal Pharmaceuticals by 172.8% in the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 368 shares in the last quarter. Centaurus Financial Inc. purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at about $163,000. Finally, KBC Group NV lifted its holdings in Madrigal Pharmaceuticals by 73.5% in the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 258 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.